Correspondence 0001437749-24-021402 from Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc.
Date: June 27, 2024 · CIK: 0001659617 · Accession: 0001437749-24-021402
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280064
Letter
mbrx20240627_corresp.htm
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007
June 27, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Chris Edwards
Re:
Moleculin Biotech, Inc.
Registration Statement on Form S-3
Registration No. 333-280064
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on July 1, 2024, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP 1 filename1.htm mbrx20240627_corresp.htm Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 77007 June 27, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Chris Edwards Re: Moleculin Biotech, Inc. Registration Statement on Form S-3 Registration No. 333-280064 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on July 1, 2024, or as soon thereafter as possible on such date. Very truly yours, Moleculin Biotech, Inc. By: /s/ Jonathan P. Foster Name: Jonathan P. Foster Title: Chief Financial Officer